VPC
BCAX

Vestal Point Capital’s Bicara Therapeutics BCAX Stock Holding History

Vestal Point Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156M Sell
5,250,000
-175,000
-3% -$3.91M 3.64% 7
2026
Q1 		$108M Buy
5,425,000
+1,850,000
+52% +$31.8M 3.02% 8
2025
Q4 		$60.2M Sell
3,575,000
-1,525,000
-30% -$26M 2.05% 15
2025
Q3 		$80.5M Buy
5,100,000
+100,000
+2% +$1.12M 3.64% 6
2025
Q2 		$46.5M Buy
5,000,000
+2,231,025
+81% +$26.6M 2.45% 13
2025
Q1 		$36.1M Buy
2,768,975
+2,058,975
+290% +$27.3M 2.58% 11
2024
Q4 		$12.4M Buy
710,000
+285,000
+67% +$5.93M 0.73% 39
2024
Q3 		$10.8M Buy
+425,000
New +$10.8M 0.82% 30

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital's BCAX Position: Q2 2026 in Review

Vestal Point Capital reduced its Bicara Therapeutics (BCAX) stake by 3.2% in Q2 2026, selling an estimated $3.91M and leaving 5,250,000 shares worth $156M. The position accounts for 3.64% of the portfolio, ranked #7.

Vestal Point Capital first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Vestal Point Capital held 5,250,000 shares of Bicara Therapeutics worth $156M as of Q2 2026.
  • Vestal Point Capital sold 175,000 Bicara Therapeutics shares in Q2 2026, an estimated $3.91M.
  • Bicara Therapeutics made up 3.64% of Vestal Point Capital's portfolio in Q2 2026, its #7 holding.
  • Vestal Point Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.